Amgen gets early win in Regeneron lawsuit over Eylea biosimilar
WEBSept 23 (Reuters) - Regeneron (REGN.O) cannot immediately block U.S. sales of rival Amgen's (AMGN.O) proposed copy of its blockbuster eye-care drug Eylea, a federal judge in West Virginia...
Regeneron (REGN) Set for Monthly Drop on Amgen (AMGN) …
WEB3 days ago · Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that opens the door to an early launch of a competing therapy to the drugmaker...
Regeneron's Eylea biosimilar fight heats up after court ruling - STAT
WEB6 days ago · Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its blockbuster eye drug Eylea hit a legal roadblock.
Biocon Pushes to Unseal Amgen Eylea Court Filings Before Appeal
WEBAmgen Inc. is “stonewalling” public access to information about its successful avoidance of Regeneron Pharmaceuticals Inc.’s bid to block its biosimilar of the blockbuster eye drug Eylea, two competitors said in a filing urging a judge to …
Amgen's biosimilar version of Regeneron's Eylea can enter market
WEB6 days ago · As Regeneron's case plays out, Amgen could now pursue an "at-risk" biosimilar launch. Under such an approach, the biosimilar maker would be liable for damages should Regeneron ultimately...
Regeneron falls after judge denies injunction blocking Amgen
WEBRegeneron Pharmaceuticals (NASDAQ:REGN) dropped 4.5% after a judge denied the company's motion for a preliminary injunction to block an Amgen biosimilar version of Regeneron's blockbuster...
Amgen Gets Legal Win in Eylea Patent Row With Regeneron
WEB6 days ago · Regeneron’s lawsuit, filed earlier this year, alleged more than 30 counts of patent infringement against Amgen and its biosimilar to the blockbuster eye therapy Eylea.
Regeneron Appeals After Judge Declines to Block Amgen Biosimilar
WEBRegeneron Pharmaceuticals Inc. quickly appealed a judge’s order declining to block Amgen Inc.'s biosimilar version of its blockbuster eye drug Eylea while a patent-infringement suit continues.
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar …
WEB6 days ago · Shares of Regeneron Pharmaceuticals, Inc. REGN were down 4.63% after an unfavorable ruling in its lawsuit against Amgen AMGN in the United States District Court for the Northern District of West...
Regeneron asks US court to block Amgen's Eylea biosimilar
WEBJan 11, 2024 · New York-based biotech company Regeneron has sued rival Amgen in federal court in Los Angeles, alleging that Amgen's proposed biosimilar of Regeneron's blockbuster eye drug Eylea...
- Some results have been removed